CA2580151C - Stereoisomerically enriched .beta.-lactams using candida antarctica - Google Patents

Stereoisomerically enriched .beta.-lactams using candida antarctica Download PDF

Info

Publication number
CA2580151C
CA2580151C CA2580151A CA2580151A CA2580151C CA 2580151 C CA2580151 C CA 2580151C CA 2580151 A CA2580151 A CA 2580151A CA 2580151 A CA2580151 A CA 2580151A CA 2580151 C CA2580151 C CA 2580151C
Authority
CA
Canada
Prior art keywords
lipase
lactam
diyl
unsubstituted
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2580151A
Other languages
English (en)
French (fr)
Other versions
CA2580151A1 (en
Inventor
Ankush Argade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CA2580151A1 publication Critical patent/CA2580151A1/en
Application granted granted Critical
Publication of CA2580151C publication Critical patent/CA2580151C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2580151A 2004-11-15 2005-11-15 Stereoisomerically enriched .beta.-lactams using candida antarctica Expired - Fee Related CA2580151C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62840104P 2004-11-15 2004-11-15
US60/628,401 2004-11-15
PCT/US2005/041276 WO2006055528A2 (en) 2004-11-15 2005-11-15 Process for the preparation of an optically acitive n-carbamate protected beta-lactam by optical resolution employing a candida antarctica lipase

Publications (2)

Publication Number Publication Date
CA2580151A1 CA2580151A1 (en) 2006-05-26
CA2580151C true CA2580151C (en) 2014-02-04

Family

ID=36190809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2580151A Expired - Fee Related CA2580151C (en) 2004-11-15 2005-11-15 Stereoisomerically enriched .beta.-lactams using candida antarctica

Country Status (10)

Country Link
US (1) US7459301B2 (https=)
EP (1) EP1812581B1 (https=)
JP (1) JP4738416B2 (https=)
AT (1) ATE421996T1 (https=)
CA (1) CA2580151C (https=)
DE (1) DE602005012597D1 (https=)
DK (1) DK1812581T3 (https=)
ES (1) ES2320364T3 (https=)
PT (1) PT1812581E (https=)
WO (1) WO2006055528A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
JP5400388B2 (ja) 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ, インコーポレイテッド キナーゼインヒビターおよびその利用
HU227663B1 (en) * 2007-07-09 2011-10-28 Univ Szegedi Resolution process
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラキナーゼインヒビターと化学療法剤の投与
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2019201279A1 (zh) * 2018-04-18 2019-10-24 广东东阳光药业有限公司 一种桥环化合物的制备方法
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520027A (ja) * 1998-07-09 2002-07-09 ロンザ ア−ゲ− (1r,4s)−2−アザビシクロ[2.2.1]ヘプタ−5−エン−3−オン誘導体の製造方法

Also Published As

Publication number Publication date
PT1812581E (pt) 2009-04-22
EP1812581B1 (en) 2009-01-28
DK1812581T3 (da) 2009-05-11
CA2580151A1 (en) 2006-05-26
JP2008520206A (ja) 2008-06-19
ES2320364T3 (es) 2009-05-21
JP4738416B2 (ja) 2011-08-03
US20060166308A1 (en) 2006-07-27
WO2006055528A2 (en) 2006-05-26
DE602005012597D1 (de) 2009-03-19
EP1812581A2 (en) 2007-08-01
ATE421996T1 (de) 2009-02-15
WO2006055528A3 (en) 2006-08-31
US7459301B2 (en) 2008-12-02

Similar Documents

Publication Publication Date Title
CA2580151C (en) Stereoisomerically enriched .beta.-lactams using candida antarctica
JP3594602B2 (ja) 酵素触媒作用アシル化による1級及び2級アミンのラセミ分割
JP3789938B2 (ja) 酵素触媒作用アシル化による1級及び2級のヘテロ原子置換アミンのラセミ体分割
JP5096435B2 (ja) 光学活性α−メチルシステイン誘導体の製造方法
EP2284174B1 (en) Intermediates for the preparation of benzoxazine derivatives and process for their preparation
US4859602A (en) Process for the preparation of stereoisomers of 1-aminoalkylphosphonic and phosphinic acids
JP2015091265A (ja) L−アミノ酸の製造方法
ES2969331T3 (es) Procedimiento enzimático para la preparación del ácido (2S)-2-[(4R)-2-oxo-4-propil-pirrolidín-1-il]butírico y su conversión en brivaracetam
EP0237983A2 (en) Process for the biotechnological preparation of L (-)-carnitine chloride
HU214702B (hu) Polihidroxi-ciklopentán-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények
EP0802901B1 (en) Novel carbamate compounds containing thiocarbamoyl group and process for preparing the same
JP2846770B2 (ja) 光学活性なトランス−2−アミノシクロヘキサノール誘導体を取得するための光学分割法
EP1705252B1 (en) Method for producing optically active N-protected-propargylglycine
Kamal et al. Lipase-catalyzed resolution of 1-chloro-3-[(4-morpholin-4-yl-1, 2, 5-thiadiazole-3-yl) oxy] propan-2-ol: Synthesis of (R)-and (S)-timolol
EP1536017B1 (en) Process for producing optically active octahydro-1H-indole-2-carboxylic acid
EP0869185B9 (en) Production of optically active sphingoid compound
HK40077947B (en) Enzymatic process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
JP2000086605A (ja) L―アリシンアセタ―ルの製造法
JPH07303495A (ja) 光学活性なプロピオン酸エステルの製造法
HU227663B1 (en) Resolution process

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191115